WO2012013850A3 - Composé destiné à traiter des maladies neurodégénératives, des troubles cognitifs et/ou des démences - Google Patents

Composé destiné à traiter des maladies neurodégénératives, des troubles cognitifs et/ou des démences Download PDF

Info

Publication number
WO2012013850A3
WO2012013850A3 PCT/ES2011/070539 ES2011070539W WO2012013850A3 WO 2012013850 A3 WO2012013850 A3 WO 2012013850A3 ES 2011070539 W ES2011070539 W ES 2011070539W WO 2012013850 A3 WO2012013850 A3 WO 2012013850A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
dementia
neurodegenerative diseases
treating neurodegenerative
cognitive deficiencies
Prior art date
Application number
PCT/ES2011/070539
Other languages
English (en)
Spanish (es)
Other versions
WO2012013850A2 (fr
Inventor
Javier Santos Burgos Muñoz
Maria del Carmen Ramos Martín
Saleta SIERRA ÁVILA
Beatriz SUÁREZ GONZÁLEZ
Juan María Alfaro Sánchez
Original Assignee
Neuron Biopharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Biopharma, S.A. filed Critical Neuron Biopharma, S.A.
Publication of WO2012013850A2 publication Critical patent/WO2012013850A2/fr
Publication of WO2012013850A3 publication Critical patent/WO2012013850A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation du composé gémifloxacine pour le traitement de maladies neurodégénératives, d'une altération cognitive légère, de troubles cognitifs, de démences, de maladies associées au vieillissement et de processus pathologiques associés à l'âge et à la progérie, et notamment de la maladie d'Alzheimer, compte tenu de la découverte de nouvelles propriétés intrinsèques à ce composé.
PCT/ES2011/070539 2010-07-26 2011-07-22 Composé destiné à traiter des maladies neurodégénératives, des troubles cognitifs et/ou des démences WO2012013850A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201001078 2010-07-26
ES201001078A ES2373598B1 (es) 2010-07-26 2010-07-26 Compuesto para tratar enfermedades neurodegenerativas, déficits cognitivos y/o demencias.

Publications (2)

Publication Number Publication Date
WO2012013850A2 WO2012013850A2 (fr) 2012-02-02
WO2012013850A3 true WO2012013850A3 (fr) 2012-03-22

Family

ID=45497530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070539 WO2012013850A2 (fr) 2010-07-26 2011-07-22 Composé destiné à traiter des maladies neurodégénératives, des troubles cognitifs et/ou des démences

Country Status (2)

Country Link
ES (1) ES2373598B1 (fr)
WO (1) WO2012013850A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680842A4 (fr) * 2011-03-02 2014-10-29 Bionomics Ltd Méthodes de traitement d'une maladie ou d'un état pathologique du système nerveux central

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US20010014670A1 (en) * 1998-01-09 2001-08-16 Brian J. Balin Treatment and diagnosis of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014670A1 (en) * 1998-01-09 2001-08-16 Brian J. Balin Treatment and diagnosis of alzheimer's disease
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMARANTE, G.W. ET AL.: "Mechanism and synthesis of pharmacologically active quinolones from Morita-Baylis-Hillman adducts", TETRAHEDRON, vol. 66, 2010, pages 4370 - 4376, XP027050806 *

Also Published As

Publication number Publication date
ES2373598B1 (es) 2012-11-14
WO2012013850A2 (fr) 2012-02-02
ES2373598A1 (es) 2012-02-07

Similar Documents

Publication Publication Date Title
EP3715345A3 (fr) Procédé de préparation d'un inhibiteur de lfa-1 et polymorphe associé
EP2519234A4 (fr) Thérapie anaplérotique pour la maladie d'alzheimer et le vieillissement du cerveau
WO2013033037A3 (fr) Nouveaux composés d'antiprion
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
WO2015095337A3 (fr) Dérivés pyrazolo [1,5-a]pyrimidine carboxamide pour le traitement de troubles cognitifs
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
WO2014028461A3 (fr) Traitement et diagnostic du mélanome
WO2012040641A3 (fr) Composés de traitement de maladies neurodégénératives
PL1940817T3 (pl) Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
WO2010059241A3 (fr) Traitement de la sclérose latérale amyotrophique
EP2977452A3 (fr) Procédés de traitement et de prévention de maladies et de troubles neurodégénératifs
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
WO2013098416A3 (fr) Composes anti-douleur
IN2012DN05186A (fr)
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
WO2011159693A3 (fr) Traitement oral de lésions ischémiques digitales
WO2009115252A3 (fr) Pyrazolamides substitués et leur utilisation
EP2750606A4 (fr) Méthodes de diagnostic et de traitement de maladies et d'affections neurologiques et neurodégénératives et procédés associés
CA2851761C (fr) Methode de diagnostic, de pronostic ou de traitement des maladies neurodegeneratives
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты
WO2011160974A3 (fr) Dérivés de statines
WO2011073370A3 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
IN2014DN09826A (fr)
WO2012013850A3 (fr) Composé destiné à traiter des maladies neurodégénératives, des troubles cognitifs et/ou des démences

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811877

Country of ref document: EP

Kind code of ref document: A2